For Patients and Their Families

Cognition Therapeutics is focused on developing innovative therapies that improve the lives of individuals with Alzheimer’s disease and other neurocognitive disorders. We deeply thank the patients, families, clinical researchers, hospitals and clinics that participate in clinical trials that are designed to test our lead drug candidate, CT1812. Every patient who participates allows us to learn more about the safety and effectiveness of this experimental medicine and contributes to the overall understanding of Alzheimer’s disease.

Current Open Trials

We are currently conducting clinical trials of our drug candidate CT1812 in Alzheimer’s disease patients. For information, please visit www.clinicaltrials.gov, an internet-based resource maintained by the National Library of Medicine of the National Institutes of Health.

Pre-approval Access to CT1812

Programs for access to an experimental medicine prior to regulatory approval, often called “compassionate use” or “expanded access” programs, exist so that physicians can request an experimental medication outside of a clinical trial setting in order to treat a patient with a serious or life-threatening condition not adequately treated with already approved medicines.

Cognition Therapeutics is currently not providing our investigational medicine, CT1812, outside of our ongoing clinical trial program. If you or a loved one are interested in participating in a clinical trial for CT1812, please visit www.clinicaltrials.gov, where we will list enrolling and planned clinical trials along with their eligibility criteria and participating clinical center locations. Talk with your doctor about these and other clinical trials listed in the database to see if they are options for you.